BIVI — BIOVIE INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1580149 ·
Last close
$1.52
Market Cap
$11.46M
52W High
$2.31
52W Low
$1.26
ADV30
225,633
Next earnings
2026-08-24
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,385,377 | -5,270,299 | 17,514,621 | 13,098,976 | 1,907,029 |
| Dec 2025 | 0 | — | -6,262,305 | -6,069,475 | 22,503,293 | 20,540,585 | 3,238,259 |
| Sep 2025 | 0 | — | -5,284,595 | -5,087,557 | 26,820,098 | 24,978,302 | 1,899,094 |
| Jun 2025 | 0 | — | -3,663,085 | -3,489,141 | 21,562,199 | 17,544,547 | 2,550,214 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,510,667
Investing CF
$0
Financing CF
$10,457,629
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.96
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-363,344,822
Inventory
—
Receivables
$195,481
ST Investments
—
EBIT TTM
$-17,416,639
Pretax Income TTM
$-17,434,591
Interest Exp TTM
$17,952
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -18,066,200 | -17,542,120 | 21,562,199 | 2,550,214 | — | -19,025,205 |
| Jun 2024 | 0 | -32,179,585 | -32,120,533 | 25,208,345 | 9,702,130 | — | -27,945,024 |
| Jun 2023 | 0 | -45,080,448 | -50,255,815 | 35,104,730 | 19,764,444 | — | -40,252,881 |
| Jun 2022 | 0 | -27,252,977 | -26,084,468 | 20,114,594 | 16,443,659 | — | -18,990,850 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMMB | Chemomab Therapeutics Ltd. | $11.36M | $1.55 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.35M | $2.56 | — |
| COCP | Cocrystal Pharma, Inc. | $11.31M | $0.82 | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.91M | $1.02 | — |
| GDTC | CytoMed Therapeutics Ltd | $11.00M | $0.93 | — |
News headlines (Yahoo Finance, 1h cache)
BioVie: Long COVID trial fully enrolled – ICYMI
2026-05-29 20:30 · Yahoo
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-05-29 13:00 · Yahoo
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
2026-05-27 12:00 · Yahoo
BioVie completes enrollment in Long COVID trial as need for treatments grows
2026-05-26 17:34 · Yahoo
BioVie completes enrollment in Phase 2 Long COVID trial
2026-05-26 13:12 · Yahoo
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2026-05-26 12:00 · Yahoo
BioVie completes final patient visit in Parkinson's drug trial
2026-05-19 12:31 · Yahoo
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
2026-05-18 12:00 · Yahoo
BioVie CEO shares insights into long COVID trial - ICYMI
2026-05-09 13:00 · Yahoo
BioVie advances long COVID trial, top-line data expected by summer
2026-05-04 15:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.